Highlights From the AAN Annual Meeting
Episode 35, Apr 30, 2021, 10:00 AM
Welcome to the NeurologyLive Mind Moments podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD. Each of them discussed data that they respectively presented at the American Academy of Neurology Annual Meeting. These presentations included novel tools for tracking cognitive decline, analyses of subpopulations of patients with migraine treated with new medicines, the disparities faced by women and Black individuals going through stroke rehabilitation, and more.
In this episode, we spoke with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD. Each of them discussed data that they respectively presented at the American Academy of Neurology Annual Meeting. These presentations included novel tools for tracking cognitive decline, analyses of subpopulations of patients with migraine treated with new medicines, the disparities faced by women and Black individuals going through stroke rehabilitation, and more.
Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
Check out NeurologyLive's complete coverage of the 2021 American Academy of Neurology Annual Meeting here: neurologylive.com/aan
Check out NeurologyLive's complete coverage of the 2021 American Academy of Neurology Annual Meeting here: neurologylive.com/aan
REFERENCES
1. Nahas S, Ning X, Cohen JM, Barash S, Campos VR, Silberstein SD. Efficacy of fremanezumab in patients with moderate and higher frequency episodic migraine. Presented at 2021 American Academy of Neurology Annual Meeting. Abstract P10.046
2. Nahas S, Jurgens TP, Kessler Y, et al. Cardiovascular safety of fremanezumab in patients with migraine and cardiovascular medical history or risk factors: A pooled analysis of phase 3 studies. Presented at 2021 American Academy of Neurology Annual Meeting. Abstract P10.034
3. Cree B, Bennett J, Weinshenker B, et al. Long-term efficacy outcomes with inebilizumab treatment in NMOSD: the N-MOmentum trial. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.076
4. Cree B, Bennett J, Weinshenker B, et al. Long-term safety outcomes with inebilizumab treatment in NMOSD: the N-MOmentum trial. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.100
5. Somani S, Nanavati H, Xiaohua Z, Lin C. African American women have lower functional performance during acute inpatient rehabilitation after intracerebral hemorrhagic strokes. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P5 073
6. Fernandez H, Odin P, Standaert D, et al. Identifying gaps in Parkinson disease patients eligible for device-aided therapies: results from using the MANAGE-PD tool in patients from G7 countries. Abstract P14.117
7. Ontaneda D, Qu J, McGinley M, et al. A Data Driven Approach to Define Disease Course Categories in MS. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.244
8. Pila S, Novak M, Weintraub S, et al. The Mobile Toolbox (MBT): A Completely Remote Platform for Cognitive Research. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P7.086
1. Nahas S, Ning X, Cohen JM, Barash S, Campos VR, Silberstein SD. Efficacy of fremanezumab in patients with moderate and higher frequency episodic migraine. Presented at 2021 American Academy of Neurology Annual Meeting. Abstract P10.046
2. Nahas S, Jurgens TP, Kessler Y, et al. Cardiovascular safety of fremanezumab in patients with migraine and cardiovascular medical history or risk factors: A pooled analysis of phase 3 studies. Presented at 2021 American Academy of Neurology Annual Meeting. Abstract P10.034
3. Cree B, Bennett J, Weinshenker B, et al. Long-term efficacy outcomes with inebilizumab treatment in NMOSD: the N-MOmentum trial. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.076
4. Cree B, Bennett J, Weinshenker B, et al. Long-term safety outcomes with inebilizumab treatment in NMOSD: the N-MOmentum trial. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.100
5. Somani S, Nanavati H, Xiaohua Z, Lin C. African American women have lower functional performance during acute inpatient rehabilitation after intracerebral hemorrhagic strokes. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P5 073
6. Fernandez H, Odin P, Standaert D, et al. Identifying gaps in Parkinson disease patients eligible for device-aided therapies: results from using the MANAGE-PD tool in patients from G7 countries. Abstract P14.117
7. Ontaneda D, Qu J, McGinley M, et al. A Data Driven Approach to Define Disease Course Categories in MS. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P15.244
8. Pila S, Novak M, Weintraub S, et al. The Mobile Toolbox (MBT): A Completely Remote Platform for Cognitive Research. Presented at 2021 American Academy of Neurology Annual Meeting; April 17-22. Abstract P7.086